ORLANDO, Fla.—AIM-HIGH, a late-breaking clinical trial presented at this year’s American Heart Association (AHA) scientific sessions, received a great deal of criticism for its design from its discussant, Philip Barter, MD, PhD; however, lead investigator William E. Boden, MD, strongly defended the design, even though he acknowledged to Cardiovascular Business that the results of the prematurely stopped trial will not change practice.
In May, the National Heart, Lung and Blood Institute stopped AIM-HIGH (co-sponsored by Abbott Laboratories), which was studying a blood lipid treatment, 18 months earlier than planned. However, Boden parsed out some of that discontinuation, including that the physicians involved learned about the trial's cessation a day after the decision. He also explained use of niacin in his clinical practice.
This video was conducted collaboratively with ClinicalTrialResults.org.